Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial

BMC Medical Research Methodology
Douglas E FariesBruce J Kinon


Little is known about the specific reasons for antipsychotic discontinuation or continuation from patients' or clinicians' perspectives. This study aimed to assess the construct validity of 2 new measures of the Reasons for Antipsychotic Discontinuation/Continuation (RAD): RAD-I (a structured interview assessing the patient's perspective) and RAD-Q (a questionnaire assessing the clinician's perspective). Data were used from a 12-week antipsychotic trial of schizophrenia patients in which the RAD was administered at study entry and at study completion (or discontinuation). Construct validity was assessed through comparisons of RAD responses, clinicians' responses to a standard patient disposition form identifying reasons for patient's study discontinuation, and several standard psychiatric measures. Percent agreement quantified the correspondence between patient and clinician scores. Patients indicating lack of improvement/worsening of positive symptoms as a 'somewhat' to 'primary' reason for medication discontinuation had statistically significantly less improvement in Positive and Negative Syndrome Scale positive score than patients not reporting these as a reason (concurrent validity). Similar results were observed for the RA...Continue Reading


Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Jan 1, 1994·Schizophrenia Bulletin·P WeidenA Frances
Nov 19, 2003·Journal of Clinical Psychopharmacology·Peter J WeidenSteven J Romano
Jun 29, 2005·Schizophrenia Research·Stefan LeuchtRolf R Engel
Aug 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sylvia ParkStephen B Soumerai
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Dec 8, 2006·The American Journal of Psychiatry·Susan M EssockJeffrey A Lieberman
Jun 29, 2007·Schizophrenia Research·C Daniel MullinsAntony D Loebel
Jul 17, 2007·Journal of Clinical Psychopharmacology·Hong Liu-SeifertBruce J Kinon
Nov 21, 2007·The British Journal of Psychiatry. Supplement·Ann M Mortimer
Nov 11, 2008·Schizophrenia Research·Robert A RosenheckJeffrey Lieberman
Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bruce J KinonJohn M Kane
Mar 3, 2011·The American Journal of Psychiatry·Jari TiihonenPasi Korhonen

❮ Previous
Next ❯


Jun 17, 2016·Journal of Clinical Psychopharmacology·Saínza GarcíaAna González-Pinto

❮ Previous
Next ❯

Clinical Trials Mentioned


Software Mentioned


Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here